lutetium has been researched along with Glioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aranda-Lara, L; Azorín-Vega, E; Santiago-Bañuelos, JA; Torres-García, E | 1 |
| Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J | 1 |
| Hens, M; Vaidyanathan, G; Welsh, P; Zalutsky, MR | 1 |
| Bigner, DD; Hens, M; Vaidyanathan, G; Zalutsky, MR; Zhao, XG | 1 |
| Bigner, DD; Hens, M; Pegram, C; Yordanov, AT; Zalutsky, MR | 1 |
5 other study(ies) available for lutetium and Glioma
| Article | Year |
|---|---|
Effect of
Topics: Antigens, Surface; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Damage; Glioma; Glutamate Carboxypeptidase II; Humans; Lutetium; Radioisotopes; Radiopharmaceuticals; Tumor Hypoxia | 2019 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Gastrins; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Purines; Radioisotopes; Signal Transduction; Temozolomide | 2016 |
Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; ErbB Receptors; Glioma; Isotope Labeling; Ligands; Lutetium; Macrocyclic Compounds; Mice; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2009 |
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; ErbB Receptors; Flow Cytometry; Glioma; Heterocyclic Compounds, 1-Ring; Humans; Isothiocyanates; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Stereoisomerism; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Topics: Animals; Antibodies, Monoclonal; Brain; Brain Neoplasms; Cell Line, Tumor; Glioma; Hydrocarbons, Acyclic; Lutetium; Macrocyclic Compounds; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Organ Specificity; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tenascin; Tissue Distribution | 2007 |